LIXTE Biotechnology Holdings Provides Update on Recent Activities
LIXTE Biotechnology provided an update on their recent activities. Key highlights include promising pre-clinical data on their compound LB-100 in a new field of cancer biology called 'activation lethality.' The findings suggest that LB-100 can force cancer cells to lose their cancer-causing properties, potentially opening new treatment strategies alongside ongoing clinical trials in lung, ovarian, and sarcoma cancers. The data was presented by Dr. René Bernards at a major cancer research conference and published in the journal Cancer Discovery.
CEO Bas van der Baan presented at the MedInvest Biotech and Pharma Investor Conference. LIXTE co-sponsored an international workshop at Harvard’s Dana Farber Cancer Institute, discussing innovative cancer therapy approaches. Clinical trials for LB-100 are underway at various prestigious institutions, including the University of Texas MD Anderson Cancer, City of Hope Cancer Center, Sarah Cannon Research Institute, and the Spanish Sarcoma Group. In February 2024, LIXTE signed an exclusive patent license agreement with the NIH. The company's latest financial data is available in their quarterly report filed with the SEC.
- Promising pre-clinical data on LB-100 in 'activation lethality' field.
- Potential new treatment strategies for lung, ovarian, and sarcoma cancers.
- Presentation of data at major cancer research conference by Dr. René Bernards.
- Participation in MedInvest Biotech and Pharma Investor Conference.
- Co-sponsorship of workshop at Harvard’s Dana Farber Cancer Institute.
- Ongoing clinical trials at prestigious institutions like the University of Texas MD Anderson Cancer Center.
- Signed exclusive patent license agreement with NIH.
- Financial data available in recent quarterly report.
- No specific financial metrics or revenue data provided in the PR.
- Unclear timelines and outcomes for the clinical trials mentioned.
- Dependence on further clinical trials to validate pre-clinical findings.
- Potential delays or risks associated with ongoing and future clinical trials.
- Lack of detailed financial performance indicators in the PR.
The recent developments regarding LIXTE Biotechnology Holdings' compound LB-100 are promising. The concept of activation lethality introduces a novel method of cancer treatment by compelling cancer cells to abandon their harmful characteristics. This could potentially revolutionize treatment strategies, complementing the company’s current clinical trials for lung, ovarian and sarcoma cancers.
It’s noteworthy that LIXTE is leveraging expertise from prominent institutions such as the Netherlands Cancer Institute and Dana Farber Cancer Institute. Collaborations with these respected institutions lend credibility to LIXTE's research and could accelerate the translation of pre-clinical findings into viable treatments.
However, investors should bear in mind that these findings are still in the pre-clinical stage. The transition from pre-clinical to clinical trials and eventually to market approval is a lengthy and uncertain process. While the data is exciting, it is essential to remain cautious until clinical efficacy and safety are thoroughly validated.
From a financial perspective, LIXTE Biotechnology Holdings has shown strategic progress. The recent filing of their Quarterly Report on Form 10-Q reveals their ongoing commitment to transparency and regulatory compliance. This move is important for maintaining investor confidence.
Moreover, the company's participation in high-profile conferences and workshops, such as at Harvard University’s Dana Farber Cancer Institute and the MedInvest Biotech and Pharma Investor Conference, plays a significant role in raising the company's profile among key stakeholders, including potential investors and collaborators. These platforms provide opportunities for networking and showcasing their research advancements.
However, it’s important to recognize that these activities, while essential for visibility and credibility, do not immediately translate into revenue or profit. The financial stability of the company will largely depend on the successful progression of their clinical trials and eventual commercial viability of their therapies.
- Publishing of Findings in Recent Pre-Clinical Study for LIXTE’s Proprietary Compound, LB-100, in New Field of Cancer Biology, “Activation Lethality”
- Presentation at MedInvest Biotech and Pharma Investor Conference
- Co-Sponsorship/Presentation of Workshop at Harvard University’s Dana Farber Cancer Institute
PASADENA, CA, May 20, 2024 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage pharmaceutical company developing a new class of cancer therapy to enhance chemotherapy and immunotherapy, today provided an update on the Company’s recent activities, including notable pre-clinical developments.
“LIXTE continues to make progress with its proprietary compound, LB-100, in ongoing clinical trials for lung, ovarian and sarcoma cancers,” said Bas van der Baan, LIXTE’s President and Chief Executive Officer. “We also are pleased with the findings of recent pre-clinical data with LB-100 in an entirely new field of cancer biology -- activation lethality -- that we believe has outstanding potential in advancing new treatment options.”
Recent Company highlights include:
- Pre-clinical studies in a new field of cancer biology -- activation lethality -- have shown that LB-100 can force cancer cells to give up their cancer-causing properties. The findings open a potentially new treatment strategy in addition to LIXTE’s current three ongoing clinical trials. René Bernards, Ph.D., a leader in the field of molecular carcinogenesis and Senior Staff Scientist at the Netherlands Cancer Institute, presented the new pre-clinical data at the Joint Conference of European and American Associations for Cancer Research in Dublin, Ireland. The paper, “Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy,” was posted in the online medical journal Cancer Discovery on April 30, 2024. Dr. Bernards is a member of LIXTE’s Board of Directors.
- Bas van der Baan, LIXTE’s President and Chief Executive Officer, presented at the MedInvest Biotech and Pharma Investor Conference on April 3, 2024 in New York City. The two-day event featured presentations from more than 40 companies, developing and commercializing technologies across a broad spectrum of indications, including oncology. The conference also featured talks from key industry opinion leaders, investor panel discussions, and conversations with the National Cancer Institute on patenting, facilitating collaborations, licensing and technology analysis and marketing.
- LIXTE co-sponsored an international scientific workshop on “Therapeutic Over-Activation in Cancer” at Harvard University’s Dana Farber Cancer Institute in Boston, Massachusetts on May 9 and 10, 2024. The workshop brought together leading experts from the pharmaceutical industry and academia who discussed a radically different approach to cancer therapy that is being spearheaded by LIXTE’s outsourced research team at the Netherlands Cancer Institute.
LIXTE has clinical trials underway at the University of Texas MD Anderson Cancer (ovarian clear cell carcinoma); City of Hope Cancer Center and the Sarah Cannon Research Institute (small cell lung cancer); and the Spanish Sarcoma Group (advanced soft tissue sarcoma). In February 2024, LIXTE signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke (NINDS) and the National Cancer Institute (NCI), each an institute or center of the National Institute of Health (NIH).
Click here for a brief video overview by LIXTE’s Chief Executive Officer.
Filing of Quarterly Report on Form 10-Q for the three months ended March 31, 2024
Additional information with respect to LIXTE’s business, clinical trials and financial condition is contained in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2024, which has been filed with the U.S. Securities and Exchange Commission at www.sec.gov.
About LIXTE Biotechnology Holdings, Inc.
LIXTE Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated in cancer patients at doses associated with anti-cancer activity. Based on extensive published pre-clinical data (see www.lixte.com), LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer. LIXTE's new approach has no known competitors and is covered by a comprehensive patent portfolio. Proof-of-concept clinical trials are in progress. Additional information about LIXTE can be found at www.lixte.com.
Forward-Looking Statement Disclaimer
This announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal costs to protect and maintain the Company's intellectual property worldwide, and the Company’s ability to obtain and maintain compliance with Nasdaq’s continued listing requirements, are all forward-looking statements. These statements are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly)," "continue," "forecast," "predict," "plan," "may," "will," "could," "would," "should," "expect" or the negative of such terms or other comparable terminology.
The Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general economic factors.
Readers are urged to read the risk factors set forth in the Company’s filings with the U.S. Securities and Exchange Commission at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information about LIXTE, Contact:
info@lixte.com
General Phone: (631) 830-7092
Investor Phone: (888) 289-5533
or
PondelWilkinson Inc. Investor Relations
pwinvestor@pondel.com
Roger Pondel or Laurie Berman: (310) 279-5980
FAQ
What are the recent developments for LIXTE Biotechnology's LB-100?
Where did LIXTE Biotechnology present their new LB-100 data?
What type of cancers are being targeted in LIXTE Biotechnology's ongoing clinical trials?
What significant events has LIXTE Biotechnology participated in recently?
Has LIXTE Biotechnology signed any recent agreements?
Where can I find LIXTE Biotechnology's latest financial report?
